<DOC>
	<DOCNO>NCT00703690</DOCNO>
	<brief_summary>This clinical trial patient Metabolic Syndrome Dyslipidemia study effect MK0767 triglyceride .</brief_summary>
	<brief_title>MK0767 Metabolic Syndrome-Dyslipidemia ( 0767-016 )</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Fenofibrate</mesh_term>
	<criteria>Patients Metabolic Syndrome Dyslipidemia age 21 65 Patients eligible study triglyceride level within protocol specify range least 2 criterion Metabolic Syndrome define NCEP Patients history diabetes mellitus , partial ileal bypass , intolerant fibric acid derivative , require continuous oral corticosteroid , take antiseizure medication , document coronary heart disease , renal insufficiency , proteinuria , viral hepatitis , cholelithiasis gallbladder disease , pancreatitis , neoplastic disease Patient cyclical estrogen medication Patient take lipidlowering agent include fibric acid derivative , bile acid sequestrants , HMG CoA reductase inhibitor nicotinic acid derivative within 8 week probucol within 1 year prior visit 2</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>